Gastroesophageal junction adenocarcinoma

Summary

Gastroesophageal junction adenocarcinoma (MONDO:0003219) is a disease with 1 cohort gene and 375 clinical trials. Molecularly, ERBB2 Amplification confers sensitivity to Pembrolizumab + Trastuzumab + Chemotherapy in Gastroesophageal Junction Adenocarcinoma (CIViC Level A); 4 further subtype–drug associations are mapped below. Top therapeutic interventions include ramucirumab, irinotecan, and trastuzumab deruxtecan.

At a glance

• Cohort genes: 1
• Clinical trials: 375
• Precision-medicine evidence (CIViC): 5 subtype–drug associations

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	gastroesophageal junction adenocarcinoma
Mondo ID	MONDO:0003219
DOID	DOID:4944
NCIT	C9296
UMLS	C1332166
MedGen	231030
Anatomy (UBERON)	UBERON:0007650
Is cancer (heuristic)	no

Also known as: adenocarcinoma - GEJ · adenocarcinoma of cardioesophageal junction · adenocarcinoma of gastroesophageal junction · adenocarcinoma of the cardioesophageal junction · adenocarcinoma of the EG junction · adenocarcinoma of the esophagogastric junction · adenocarcinoma of the gastroesophageal junction · adenocarcinoma of the GE junction · esophagogastric adenocarcinoma · esophagogastric junction adenocarcinoma · gastroesophageal junction adenocarcinoma

Data availability: 4 cell lines · 11 intOGen driver records.

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › gastroesophageal junction adenocarcinoma

Related subtypes (63): epididymal adenocarcinoma, rete testis adenocarcinoma, seminal vesicle adenocarcinoma, ethmoid sinus adenocarcinoma, lacrimal gland adenocarcinoma, papillary adenocarcinoma, fallopian tube adenocarcinoma, bladder adenocarcinoma, ovarian adenocarcinoma, trabecular adenocarcinoma, middle ear adenocarcinoma, bile duct adenocarcinoma, granular cell carcinoma, small intestine adenocarcinoma, urethra adenocarcinoma, villous adenocarcinoma, thymus gland adenocarcinoma, nasal cavity adenocarcinoma, ureter adenocarcinoma, adenocarcinoma in situ, maxillary sinus adenocarcinoma, mucinous adenocarcinoma, acinar cell carcinoma, adenoid cystic carcinoma, breast adenocarcinoma, clear cell adenocarcinoma, colorectal adenocarcinoma, endometrioid adenocarcinoma, esophageal adenocarcinoma, gastric adenocarcinoma, lung adenocarcinoma, prostate adenocarcinoma, renal cell carcinoma, signet ring cell carcinoma, cervical adenocarcinoma, serous adenocarcinoma, endometrium adenocarcinoma, sweat gland carcinoma, cystadenocarcinoma, tubular adenocarcinoma, mesonephric adenocarcinoma, scirrhous adenocarcinoma, pancreatic adenocarcinoma, follicular variant thyroid gland papillary carcinoma, gallbladder adenocarcinoma, hepatoid adenocarcinoma, intestinal type adenocarcinoma, micropapillary serous carcinoma, minor salivary gland adenocarcinoma, poorly differentiated thyroid gland carcinoma, salivary gland basal cell adenocarcinoma, submandibular gland adenocarcinoma, sebaceous adenocarcinoma, hepatocellular carcinoma, parathyroid gland carcinoma, pituitary adenocarcinoma, vaginal adenocarcinoma, Paget disease, diffuse type adenocarcinoma, vulvar adenocarcinoma, thyroid gland adenocarcinoma, gastroesophageal adenocarcinoma, adenoacanthoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 4 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
ERBB2	Orphanet:213726	Serous carcinoma of the corpus uteri
ERBB2	Orphanet:2800	Extramammary Paget disease
ERBB2	Orphanet:388	Hirschsprung disease
ERBB2	Orphanet:99976	Adenocarcinoma of the oesophagus and oesophagogastric junction

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

Subset	Genes
civic_only	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
ERBB2	HGNC:3430	ENSG00000141736	P04626	Receptor tyrosine-protein kinase erbB-2	civic_evidence

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
ERBB2	Receptor tyrosine-protein kinase erbB-2	Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding.

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Kinase	1	27.7×	0.036

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
ERBB2	Kinase	yes	2.7.10.1	Rcpt_L-dom, Prot_kinase_dom, Ser-Thr/Tyr_kinase_cat_dom

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	1
unknown	0

Top tissues across cohort

Tissue	Cohort genes
lower esophagus mucosa	1
right uterine tube	1
sural nerve	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
ERBB2	276	ubiquitous	marker	lower esophagus mucosa, right uterine tube, sural nerve

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
ERBB2	9,659

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
ERBB2	P04626	63

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 33. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
PLCG1 events in ERBB2 signaling	1	2855.0×	0.001	ERBB2
Drug-mediated inhibition of ERBB2 signaling	1	2855.0×	0.001	ERBB2
Resistance of ERBB2 KD mutants to trastuzumab	1	2855.0×	0.001	ERBB2
Resistance of ERBB2 KD mutants to sapitinib	1	2855.0×	0.001	ERBB2
Resistance of ERBB2 KD mutants to tesevatinib	1	2855.0×	0.001	ERBB2
Resistance of ERBB2 KD mutants to neratinib	1	2855.0×	0.001	ERBB2
Resistance of ERBB2 KD mutants to osimertinib	1	2855.0×	0.001	ERBB2
Resistance of ERBB2 KD mutants to afatinib	1	2855.0×	0.001	ERBB2
Resistance of ERBB2 KD mutants to AEE788	1	2855.0×	0.001	ERBB2
Resistance of ERBB2 KD mutants to lapatinib	1	2855.0×	0.001	ERBB2
Drug resistance in ERBB2 TMD/JMD mutants	1	2855.0×	0.001	ERBB2
GRB7 events in ERBB2 signaling	1	1903.3×	0.001	ERBB2
Constitutive Signaling by Overexpressed ERBB2	1	951.7×	0.002	ERBB2
Downregulation of ERBB2:ERBB3 signaling	1	815.7×	0.002	ERBB2
ERBB2 Activates PTK6 Signaling	1	815.7×	0.002	ERBB2
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors	1	761.3×	0.002	ERBB2
Developmental Lineage of Mammary Stem Cells	1	761.3×	0.002	ERBB2
ERBB2 Regulates Cell Motility	1	713.8×	0.002	ERBB2
PI3K events in ERBB2 signaling	1	671.8×	0.002	ERBB2
Signaling by ERBB2 ECD mutants	1	671.8×	0.002	ERBB2
GRB2 events in ERBB2 signaling	1	634.4×	0.002	ERBB2
Sema4D induced cell migration and growth-cone collapse	1	571.0×	0.003	ERBB2
Developmental Lineage of Mammary Gland Myoepithelial Cells	1	543.8×	0.003	ERBB2
SHC1 events in ERBB2 signaling	1	475.8×	0.003	ERBB2
Signaling by ERBB2 TMD/JMD mutants	1	475.8×	0.003	ERBB2
Developmental Lineage of Mammary Gland Luminal Epithelial Cells	1	456.8×	0.003	ERBB2
Signaling by ERBB2 KD Mutants	1	423.0×	0.003	ERBB2
Downregulation of ERBB2 signaling	1	380.7×	0.003	ERBB2
Signaling by ERBB2	1	346.1×	0.003	ERBB2
Constitutive Signaling by Aberrant PI3K in Cancer	1	126.9×	0.009	ERBB2

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
immature T cell proliferation in thymus	1	3370.4×	0.004	ERBB2
negative regulation of immature T cell proliferation in thymus	1	2808.7×	0.004	ERBB2
ERBB2-ERBB4 signaling pathway	1	2808.7×	0.004	ERBB2
regulation of microtubule-based process	1	1872.4×	0.004	ERBB2
ERBB2-ERBB3 signaling pathway	1	1685.2×	0.004	ERBB2
ERBB2-EGFR signaling pathway	1	1685.2×	0.004	ERBB2
enzyme-linked receptor protein signaling pathway	1	1296.3×	0.004	ERBB2
Schwann cell development	1	1053.2×	0.005	ERBB2
neurotransmitter receptor localization to postsynaptic specialization membrane	1	802.5×	0.005	ERBB2
motor neuron axon guidance	1	702.2×	0.005	ERBB2
positive regulation of MAP kinase activity	1	648.1×	0.005	ERBB2
positive regulation of transcription by RNA polymerase I	1	648.1×	0.005	ERBB2
positive regulation of Rho protein signal transduction	1	581.1×	0.005	ERBB2
regulation of ERK1 and ERK2 cascade	1	581.1×	0.005	ERBB2
positive regulation of protein targeting to membrane	1	561.7×	0.005	ERBB2
neuromuscular junction development	1	526.6×	0.005	ERBB2
peptidyl-tyrosine phosphorylation	1	421.3×	0.005	ERBB2
regulation of angiogenesis	1	421.3×	0.005	ERBB2
oligodendrocyte differentiation	1	421.3×	0.005	ERBB2
semaphorin-plexin signaling pathway	1	401.2×	0.005	ERBB2
cellular response to growth factor stimulus	1	318.0×	0.006	ERBB2
cellular response to epidermal growth factor stimulus	1	318.0×	0.006	ERBB2
positive regulation of cell adhesion	1	271.8×	0.006	ERBB2
myelination	1	251.5×	0.006	ERBB2
epidermal growth factor receptor signaling pathway	1	247.8×	0.006	ERBB2
positive regulation of epithelial cell proliferation	1	244.2×	0.006	ERBB2
wound healing	1	227.7×	0.006	ERBB2
positive regulation of translation	1	227.7×	0.006	ERBB2
phosphatidylinositol 3-kinase/protein kinase B signal transduction	1	210.7×	0.007	ERBB2
positive regulation of cell growth	1	183.2×	0.007	ERBB2

Therapeutics

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 0

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
ERBB2	CLOTRIMAZOLE

Top cohort targets by molecule count

Symbol	Molecules	Max phase
ERBB2	83	4

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
CLOTRIMAZOLE	4	ERBB2
ERLOTINIB HYDROCHLORIDE	4	ERBB2
PONATINIB	4	ERBB2
AFATINIB	4	ERBB2
LAPATINIB DITOSYLATE	4	ERBB2
SORAFENIB	4	ERBB2
NERATINIB	4	ERBB2
IBRUTINIB	4	ERBB2
AFATINIB DIMALEATE	4	ERBB2
CABOZANTINIB	4	ERBB2
DACOMITINIB	4	ERBB2
DACOMITINIB ANHYDROUS	4	ERBB2
VANDETANIB	4	ERBB2
TRIBROMSALAN	4	ERBB2
BOSUTINIB	4	ERBB2
BITHIONOL	4	ERBB2
ASTEMIZOLE	4	ERBB2
EBASTINE	4	ERBB2
OSIMERTINIB	4	ERBB2
BRIGATINIB	4	ERBB2
ACALABRUTINIB	4	ERBB2
ZANUBRUTINIB	4	ERBB2
TUCATINIB	4	ERBB2
TIRABRUTINIB	4	ERBB2
PACLITAXEL	4	ERBB2
LAZERTINIB	4	ERBB2
HEXACHLOROPHENE	4	ERBB2
DOXORUBICIN	4	ERBB2
DASATINIB	4	ERBB2
ERLOTINIB	4	ERBB2

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
ERBB2	1,221	Binding:1136, Functional:79, ADMET:6

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
ERBB2	2.7.10.1	receptor protein-tyrosine kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
ERBB2	1,221

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

27 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
CLOTRIMAZOLE	4	ERBB2
PONATINIB	4	ERBB2
AFATINIB	4	ERBB2
LAPATINIB DITOSYLATE	4	ERBB2
SORAFENIB	4	ERBB2
NERATINIB	4	ERBB2
IBRUTINIB	4	ERBB2
AFATINIB DIMALEATE	4	ERBB2
CABOZANTINIB	4	ERBB2
DACOMITINIB	4	ERBB2
DACOMITINIB ANHYDROUS	4	ERBB2
TRIBROMSALAN	4	ERBB2
BOSUTINIB	4	ERBB2
BITHIONOL	4	ERBB2
ASTEMIZOLE	4	ERBB2
EBASTINE	4	ERBB2
OSIMERTINIB	4	ERBB2
BRIGATINIB	4	ERBB2
ACALABRUTINIB	4	ERBB2
ZANUBRUTINIB	4	ERBB2
TIRABRUTINIB	4	ERBB2
PACLITAXEL	4	ERBB2
LAZERTINIB	4	ERBB2
HEXACHLOROPHENE	4	ERBB2
DOXORUBICIN	4	ERBB2
DASATINIB	4	ERBB2
ERLOTINIB	4	ERBB2

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	ERBB2
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Clinical trials & evidence

Clinical trials

Clinical trials: 375.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	167
PHASE1	56
PHASE1/PHASE2	49
Not specified	46
PHASE3	37
PHASE2/PHASE3	13
PHASE4	5
EARLY_PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07132528	PHASE4	NOT_YET_RECRUITING	Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction of Gastric Cancer
NCT07149181	PHASE4	NOT_YET_RECRUITING	Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regimens in Patients With Resectable Gastric Cancer/Adenocarcinoma of the Esophagogastric Junction After Radical Surgery
NCT07161453	PHASE4	NOT_YET_RECRUITING	Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinoma of the Esophagogastric Junction Who Underwent Radical Surgery After Neoadjuvant Chemotherapy Combined With Immunotherapy and Achieved pCR in Postoperative Pathology
NCT07502027	PHASE4	NOT_YET_RECRUITING	A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma
NCT02426034	PHASE4	COMPLETED	A Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer
NCT02509286	PHASE3	ACTIVE_NOT_RECRUITING	Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus
NCT04375605	PHASE3	ACTIVE_NOT_RECRUITING	Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ
NCT04447352	PHASE3	RECRUITING	HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)
NCT04704934	PHASE3	ACTIVE_NOT_RECRUITING	Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
NCT05002127	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
NCT05111626	PHASE3	ACTIVE_NOT_RECRUITING	Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
NCT05180734	PHASE3	ACTIVE_NOT_RECRUITING	PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer
NCT05677490	PHASE3	RECRUITING	mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
NCT05978050	PHASE3	RECRUITING	Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma
NCT06028737	PHASE2/PHASE3	RECRUITING	Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer
NCT06123494	PHASE3	RECRUITING	SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
NCT06203600	PHASE2/PHASE3	RECRUITING	Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
NCT06206733	PHASE3	ACTIVE_NOT_RECRUITING	ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma
NCT06221748	PHASE2/PHASE3	RECRUITING	DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
NCT06238843	PHASE3	ACTIVE_NOT_RECRUITING	A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator’s Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)
NCT06649292	PHASE3	RECRUITING	SHR-A1904 Compared With Investigator’s Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT06764875	PHASE3	RECRUITING	A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06841679	PHASE2/PHASE3	RECRUITING	Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07001748	PHASE2/PHASE3	RECRUITING	Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
NCT07043400	PHASE3	RECRUITING	A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07118527	PHASE3	RECRUITING	A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07152405	PHASE3	RECRUITING	A Study of BL-M07D1 Versus Investigator’s Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Adenocarcinoma
NCT07284134	PHASE3	RECRUITING	JS107 vs Investigator’s Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.
NCT07431281	PHASE3	RECRUITING	Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
NCT07449780	PHASE3	NOT_YET_RECRUITING	A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
NCT07508956	PHASE3	NOT_YET_RECRUITING	Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment
NCT07518147	PHASE3	NOT_YET_RECRUITING	A Study Comparing BL-M05D1 With the Investigator’s Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment
NCT07603349	PHASE2/PHASE3	NOT_YET_RECRUITING	Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma
NCT00978549	PHASE3	COMPLETED	Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer
NCT01107639	PHASE3	COMPLETED	Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery
NCT01196390	PHASE3	COMPLETED	Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
NCT01243398	PHASE3	COMPLETED	Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy
NCT01523015	PHASE2/PHASE3	UNKNOWN	Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction
NCT01640782	PHASE3	COMPLETED	Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach
NCT01962246	PHASE2/PHASE3	COMPLETED	Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
RAMUCIRUMAB	4	19
IRINOTECAN	4	9
TRASTUZUMAB DERUXTECAN	4	6
GEMCITABINE	4	4
PEMBROLIZUMAB	4	3
TISLELIZUMAB	4	3
TRIFLURIDINE	4	3
FRUQUINTINIB	4	2
INFIGRATINIB	4	2
NINTEDANIB	4	2
REGORAFENIB	4	2
TIPIRACIL HYDROCHLORIDE	4	2
TREMELIMUMAB	4	2
TUCATINIB	4	2
VANDETANIB	4	2
ZANIDATAMAB	4	2
ABEMACICLIB	4	1
AVELUMAB	4	1
CETUXIMAB	4	1
DOSTARLIMAB	4	1
EPIRUBICIN HYDROCHLORIDE	4	1
ERLOTINIB HYDROCHLORIDE	4	1
FLUDEOXYGLUCOSE F 18	4	1
FUTIBATINIB	4	1
IPILIMUMAB	4	1
ITRACONAZOLE	4	1
NIRAPARIB	4	1
NIVOLUMAB	4	1
OLAPARIB	4	1
PANITUMUMAB	4	1

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 5 predictive associations from 5 curated evidence items.

Molecular subtype	Therapy	Effect	Level	CIViC
ERBB2 Amplification	Pembrolizumab + Trastuzumab + Chemotherapy	Sensitivity/Response	CIViC A	EID11252
ERBB2 Amplification	Trastuzumab	Sensitivity/Response	CIViC A	EID11254
ERBB2 Amplification	Trastuzumab + Chemotherapy	Sensitivity/Response	CIViC A	EID11256
ERBB2 Overexpression	Trastuzumab	Sensitivity/Response	CIViC B	EID7062
ERBB2 Overexpression	Ramucirumab	Reduced Sensitivity	CIViC B	EID7064